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ABSTRACT 
Objective: To evaluate a brain tissue probe for intracranial pressure (ICP) and temperature (TEMP) 
monitoring as well as determination of cerebral hemodynamics using a near infrared spectroscopy 
(NIRS) and indocyanine green (ICG) dye dilution method (NIRS-ICP probe). 
Methods: The NIRS-ICP probe was applied after aneurysmal subarachnoid hemorrhage if multimodal 
monitoring was established due to poor neurological condition. ICP and TEMP values were obtained 
from ventricular catheters and systemic temperature sensors. Repeated NIRS-ICG measurements (2 
injections within 30 minutes) were performed daily for determination of cerebral blood flow (CBF), 
cerebral blood volume (CBV) and mean transit time of ICG (mttICG). Delayed cerebral ischemia was 
defined as brain tissue oxygen tension <20 mmHg and/or lactate-pyruvate-ratio >35. 
Results: A total of 128 NIRS-ICG measurements were performed in 10 patients. The correlation 
coefficient between ICP and TEMP values obtained with the NIRS-ICP probe and values from routine 
monitoring was r=0.72 and r=0.96, respectively. The mean value was 30.3 ± 13.6 ml/100g/min for 
CBF, 3.3 ± 1.2 ml/100g for CBV, and 6.8 ± 1.6 sec for mttICG. The coefficient of variation from 
repeated NIRS-ICG measurements was 10.9% for CBF, 11.7% for CBV, and 3.8% for mttICG. The 
sensitivity for delayed cerebral ischemia detection was 85% and the specificity 83% using a CBF-
threshold of 25 ml/100g/min. 
Conclusion: Multimodal monitoring using the NIRS-ICP probe is feasible with high reproducibility 
of measurement values and the ability to detect delayed cerebral ischemia. No safety concerns exist 
for the routine clinical use of the NIRS-ICP probe. 
 
KEY WORDS 
Neuromonitoring; delayed cerebral ischemia; near infrared spectroscopy; indocyanine green; cerebral 
blood flow; intracranial pressure 
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INTRODUCTION 
Intracranial pressure (ICP) monitoring is widely accepted in the management of patients with severe 
brain injury who are at risk of intracranial hypertension leading to secondary brain damage 1. 
However, given the complexity of vasospasm pathophysiology, ICP monitoring alone is insufficient 
in patients with high-grade aneurysmal subarachnoid hemorrhage (aSAH) 2,3. In recent years, 
accumulating clinical evidence suggests that multimodal neuromonitoring including cerebral blood 
flow (CBF), oxygenation and metabolism can help to avoid delayed cerebral ischemia (DCI) in 
individual patients 4-6.  
 
Determination of CBF is of particular importance within the context of multimodal neuromonitoring, 
because CBF is the key determinant of cerebral oxygenation and glucose supply. In 2000, thermal 
diffusion flowmetry for continuous bedside assessment of CBF was introduced and potential clinical 
benefits were demonstrated in patients with symptomatic vasospasm after aSAH 7,8. However, the 
clinical application remains limited because of reduced reliability of CBF measurements in patients 
with fever and hemodynamic instability 9. 
 
We tested a new multimodal brain tissue probe for combined ICP and temperature (TEMP) 
monitoring as well as determination of cerebral hemodynamics and oxygenation (NeMo® Probe and 
NeMo® System, NeMoDevices AG, Zurich, Switzerland). Relative changes in oxy- and 
deoxyhemoglobin are provided continuously using fiberoptics for near infrared spectroscopy (NIRS). 
Additionally, measurements of cerebral hemodynamics are based on a combined NIRS and 
indocyanine green (ICG) dye dilution mode 10. After intravenous injection of ICG, quantitative 
assessment of the mean transit time of the dye (mttICG), cerebral blood volume (CBV) and CBF is 
provided at the patients’ bedside. The safety and proof of concept has been documented in 
experimental studies and preliminary case reports 11-15. 
 
The new combined NIRS-ICP probe may offer enhanced modality modes without an additional 
surgical procedure in patients if ICP monitoring is indicated. The aim of this study was to evaluate the 
reproducibility of measurement values using the NIRS-ICP probe and the ability to detect DCI in 
patients with aSAH. 
 
 
CLINICAL MATERIAL AND METHODS 
This prospective observational study was conducted at the University Zurich and University 
Heidelberg. Approval was obtained from local institutional review boards and national regulatory 
authorities (Swiss Agency for Therapeutic Products and German Federal Institute for Drugs and 
Medical Devices). All patients or their legal representatives gave written informed consent.  
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Study Population and Treatment 
We enrolled patients with severe aSAH who had been admitted to the neurointensive care unit after 
uneventful aneurysm treatment. If continued sedation was necessary due to poor neurological 
condition, multimodal neuromonitoring (ICP, brain tissue oxygen tension (ptiO2), and microdialysis) 
were established for at least 72 hours. Patients with coagulopathy and/or known allergic reaction 
against contrast agents containing iodine or ICG were excluded. Other exclusion criteria were age <18 
or >75 years, thyroid disease causing hyperthyroidism, significant kidney and/or liver disease, and a 
known or potential pregnancy. All patients remained intubated and artificially ventilated and 
intraventricular catheters were implanted due to acute hydrocephalus (Bactiseal® EVD Catheter, 
CODMAN, Johnson & Johnson, Raynham, USA). Temperature (TEMP) was measured using 
catheter-tipped sensors in the arterial line or urinary bladder. Intracranial hypertension and 
hemodynamic relevant vasospasm were treated according to recommendations from the Neurocritical 
Care Society 16. There were no study specific protocols for any interventions. Therapeutic decisions 
were not based on results obtained by the NIRS-ICP probe.  
 
Multimodal Neuromonitoring using the NIRS-ICP probe 
The NIRS-ICP probe (NeMo® Probe, NeMoDevices AG, Zurich, Switzerland) is a parenchymal 
probe with sensors for ICP and TEMP monitoring additionally supplied with optical fibers for NIRS, 
providing continuous measurements of oxy- and deoxyhemoglobin (Figure 1). A combined NIRS and 
ICG dye dilution mode was applied for quantitative assessment of CBF, CBV and mttICG 10,11. With 
NIRS-ICG dilution, ICG (ICG-Pulsion®, PULSION Medical Systems, Munich, Germany) in a dose 
of 0.3 mg/kg body weight was injected into a central venous line followed by the injection of a 10ml 
5% glucose flush. For implantation of the probe, a bolt (IM3_EU, Licox, Integra LifeScience, 
Plainsboro, USA) was inserted through a frontal burr hole placed 30 mm lateral to the midline. The 
probe was inserted through the bolt, placed into the subcortical white matter (25 mm below the dura 
mater) and secured by tightening the bolt adapter. The probe position was verified by a post-insertion 
computed tomography (CT) scan.  
 
Monitoring of Brain Tissue Oxygen and Metabolism 
Monitoring cerebral oxygenation and metabolism was performed in all patients. PtiO2 was measured 
using a Clark type electrode (CC1.SB, Licox, Integra LifeScience, Plainsboro, USA) and extracellular 
concentrations of energy metabolism (glucose, lactate, pyruvate) were analyzed using cerebral 
microdialysis (CMA 70, CMA Mikrodialysis, Solna, Sweden). Both probes were inserted parallel to 
the NIRS-ICP probe using the same bolt and secured using the Luer lock connector. 
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Definition of DCI 
Because all patients in this study were comatose and/or sedated, the definition of DCI was based on 
findings of ptiO2 measurements and microdialysis as previously reported 5,6. Thus DCI was defined as 
cerebral hypoxia (ptiO2 <20 mmHg) and/or metabolic compromise (glucose level <1.0 mmol/l and 
lactate/pyruvate ratio >35), indicating secondary ischemia with increased risk of further brain damage. 
 
Study Protocol 
Following aneurysm clipping or coiling, the NIRS-ICP probe was inserted ipsilateral to the 
hemisphere with the highest risk to develop secondary ischemia. Post-insertion CT scan verified 
probe location. Repeated NIRS-ICG dye dilution measurements (2 ICG injections within 20-30 
minutes), providing absolute values of CBF, CBV and mttICG, were performed daily during an 
observation period of up to 8 days. Measurement values of ICP, TEMP, ptiO2, extracellular glucose 
and lactate/pyruvate ratio were recorded in parallel to each dye dilution measurement.  
 
Statistical Analysis 
Statistical analysis was performed using Excel® (Version 14.5.5, Microsoft®, USA) and Prism Graph 
software (Prism 5.0c, GraphPad Software, Inc., USA). Results are presented as mean ± standard 
deviation unless otherwise indicated. Physiological parameters were compared using the Mann-
Whitney test. A p-value <0.05 was considered statistical significant. The accuracy of ICP and TEMP 
values was assessed using Spearman correlation and Bland-Altman plot. The mean difference (bias) 
and 95% confidence interval (limits of agreement) were calculated by plotting the difference against 
their mean 17. The reproducibility of NIRS-ICG measurements was evaluated using the coefficient of 
variation from repeated measurements, which was calculated as the ratio of the standard deviation to 
the mean (coefficient of variation = standard deviation / mean) 18. The ability to predict DCI was 
analysed using ROC curves representing the combination of the sensitivity (true positive rate) and 
specificity (true negative rate) for each possible diagnostic threshold of CBF, CBV and mttICG. The 
ability to detect DCI was present if the area under the curve and the lower bound of a 95% confidence 
interval was >0.5 19. 
 
 
RESULTS 
Study Population 
Ten patients with a mean age of 47.2 ± 9.4 years were included in the study. All aneurysms were 
located in the anterior circulation, of which 4 were treated with clipping, 4 with coiling and 2 with 
clipping after incomplete coiling. The NIRS-ICP probe was implanted ipsilateral to the aneurysm in 9 
patients and bilaterally in 1 patient. The day of probe insertion was on average 3.3 ± 2.1 days after 
aSAH. A total of 128 ICG injections were performed during an average monitoring period of 6.4 ± 
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1.9 days. The average number of ICG injections per patient was 13.3 ± 3.2. There were no 
complications related to probe implantation and/or NIRS-ICG dye dilution measurements. 
 
Accuracy of Intracranial Pressure and Brain Temperature Monitoring 
A total of 42-paired ICP and 35-paired TEMP values were analyzed. Mean ICPNeMo and ICPControl (14.8 
± 6.4 mmHg versus 12.8 ± 4.5 mmHg; p=0.147) as well as TEMPNeMo and TEMPControl (35.1 ± 1.7 °C 
versus 35.6 ± 1.6 °C; p=0.165) did not differ significantly. The scatter and Bland-Altman plots are 
displayed in Figure 2. There was a good correlation between ICPNeMo and ICPControl (r=0.72, 95% CI 
0.53-0.84; p<0.0001). The mean bias of all ICP measurements was 2.1 mmHg with limits of 
agreement of -6.9 to 11.0 mmHg. A strong correlation was found between TEMPNeMo and TEMPControl 
(r=0.96, 95% CI 0.93-0.98; p<0.0001) with a mean bias of 0.01 °C and limits of agreement of -0.5 to 
0.5 °C.  
 
Reproducibility of repeated measurements using the NIRS-ICG dye dilution method 
Estimation of cerebral hemodynamics was feasible in 122 of 128 NIRS-ICG measurements. 
Measurement values were not available after 6 ICG injections due to artifacts or insufficient signal to 
noise ratio. The mean value was 30.3 ± 13.6 ml/100g/min for CBF, 3.3 ± 1.2 ml/100g for CBV, and 
6.8 ± 1.6 sec for mttICG. The reproducibility of measurement values was analyzed using the 
coefficient of variation from 59-pairs of repeated NIRS-ICG measurements. Due to missing values the 
coefficient of variation could not be calculated in 5-pairs of repeated NIRS-ICG measurements. The 
observed range of CBF, CBV, and mttICG values is displayed in Table 1. The reproducibility of 
repeated NIRS-ICG measurements was high with a mean coefficient of variation of 10.9% for CBF, 
11.7% for CBV, and 3.8% for mttICG.  
 
Detection of Delayed Cerebral Ischemia 
The diagnosis of DCI was established in 7 patients. A total of 52 of 122 NIRS-ICG measurements 
were performed with DCI. The values for CBF, CBV, and mttICG are presented in Table 2. Both CBF 
and CBV were significantly reduced, whereas mttICG increased with DCI. Figure 3 shows the ROC 
curve generated for each possible diagnostic cutoff. CBF measurements showed the largest area under 
the curve and proved to be superior to the information obtained by CBV and mttICG alone. The data 
used for prediction of DCI with respect to a chosen cutoff value is presented in Table 3.  
 
 
DISCUSSION 
The preliminary results demonstrate that multimodal neuromonitoring using the NIRS-ICP probe is 
feasible and safe. ICP and TEMP values obtained with the new probe agreed well with values 
obtained from ventricular drainages and systemic temperature sensors. In addition, repeated NIRS-
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ICG dye dilution measurements provided reliable values for CBF, CBV and mttICG with a high 
reproducibility under stable clinical conditions. Finally, we demonstrated that CBF measurements 
predict DCI with acceptable sensitivity and specificity.  
 
The ICP sensor of the NeMo® Probe is based on strain gauge principles of pressure transformation 
and has been validated against intraventricular pressure monitoring through a fluid-filled catheter 
connected to an external transducer. The results demonstrated sufficient agreement with a mean 
difference of 2.1 mmHg. The Bland Altman plot (with several data points above the line of identity) 
suggests a certain degree of overestimation of ICP values measured with the NeMo® Probe. This 
might be explained on one hand by pathophysiological principles, since the local information 
provided by intraparenchymal sensors may differ from ICP values obtained by intraventricular 
catheters 20. On the other hand, drift over time is a known restriction from intraparenchymal sensors 
based on strain gauge principles, which might have further contributed to the observed differences 21. 
In the context of these well-known limitations of intraparenchymal ICP monitoring, the observed 
differences were within acceptable limits 22. TEMP measurements using the NIRS-ICP probe were 
interchangeable with TEMP values obtained from systemic temperature sensors. 
 
Thermal diffusion flowmetry is so far the only technique, which allows for CBF monitoring in a 
feasible and user-friendly way directly at the bedside and there is evidence that symptomatic 
vasospasm after aSAH can be detected by the method 7,8. However, its clinical application is limited 
because measurement drifts have been reported over the 30-minute measurement cycle and between 
automatically performed recalibrations 23. In contrast to the thermal diffusion probe facilitating 
continuous CBF measurements, the NIRS-ICP probe provides serial measurements of CBF, CBV and 
mttICG based on NIRS and the intravenous injection of ICG. The results of this study confirm the 
reproducibility of measurement values with a standard deviation of 12.9 ml/100g/min and a 
coefficient of variation of 10.9 % for CBF. Kety and Schmidt reported a standard deviation of 12 
ml/100g/min from repeated CBF measurements using the nitrous oxide method 24. Olesen et al. 
reported a coefficient of variation of 8.2% from repeated CBF measurements using the xenon dilution 
method 25. These findings confirm that the reliability of the NIRS-ICP probe is comparable to 
previously reported bedside CBF monitoring systems being acceptable for clinical decision-making. 
 
The detection of DCI in comatose and/or sedated patients is based on bedside monitoring systems for 
determination of cerebral hemodynamics and oxygenation 1. Transcranial Doppler sonography has 
been shown to predict symptomatic vasospasm in the middle cerebral artery with good sensitivity 
(64%) and specificity (78%), but was less accurate in predicting anterior cerebral artery vasospasm 
(sensitivity 45% and specificity 84%) 26. Besides transcranial Doppler sonography, ptiO2 monitoring 
and cerebral microdialysis are widely accepted as diagnostic tool for early detection of DCI 5,6. In this 
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study, we compared CBF, CBV and mttICG measurements obtained by the NIRS-ICP probe with and 
without DCI. The reliable detection of DCI using CBF measurements obtained by the NIRS-ICP 
probe has been demonstrated with a sensitivity of 85% and specificity of 83% using a CBF-threshold 
of 25.0 ml/100g/min.  
 
A major limitation of the study is the lack of a gold standard for CBF measurements such as xenon-
enhanced CT as a reference method. Another limitation is that our data rely on a limited number of 
patients and thus results of this study need to be interpreted as preliminary. Furthermore, the NIRS-
ICP probe provides focal values and DCI may be missed if it occurs besides the tissue illuminated by 
the probe. Theoretical examinations indicate that the measurement volume of the NIRS-ICP probe is 
approximately 1cm3. Finally, it is important to note that continuous NIRS monitoring of cerebral 
oxygenation was not part of this study. Total hemoglobin concentrations (Hbtotal = oxyhemoglobin + 
deoxyhemoglobin) reflect CBV, and therefore, can be used for decision-making on when to perform 
NIRS-ICG dye dilution measurements in daily clinical practice. 
 
 
CONCLUSION 
In conclusion, the NIRS-ICP probe offers the benefit of multimodal monitoring of ICP, TEMP, CBF, 
CBV and oximetry parameters with one single brain tissue probe and no additional surgical risk if ICP 
monitoring is indicated anyway. The new monitoring system might be especially helpful in detection 
of DCI in patients with aSAH. The accuracy of absolute CBF values have to be further validated in 
future investigations using imaging studies such as xenon-enhanced or perfusion CT. 
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FIGURE LEGENDS 
Figure 1: A) The NeMo® Probe showing the intracranial pressure and temperature (1), electrical (2), 
and fiberoptic cable (3) ending in a single wire containing the light emitter (I) and detector (II) as well 
as the sensor for intracranial pressure (III). B) The NeMo® Control Unit containing the light source 
and detector electronics. C) A personal computer containing the NeMo® Monitor software for 
determination of cerebral hemodynamics.  D) Intubated and sedated patient with bilateral multimodal 
neuromonitoring including the NeMo® Probe (), brain tissue oxygen monitoring () and 
microdialysis (*). 
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Figure 2: Accuracy of intracranial pressure (ICP) and temperature (TEMP) measurements obtained 
by the NIRS-ICP probe. A) Correlation between ICP values obtained with the NIRS-ICP probe and 
intraventricular catheters. B) Bland Altman plot with the difference between ICP values plotted 
against their mean. C) Correlation between TEMP values obtained with the NIRS-ICP probe and 
systemic temperature sensors. B) Bland Altman plot with the difference between TEMP values 
plotted against their mean. Note – x=y, line of identity; CI confidence interval 
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Figure 3: The ability to detect DCI from 122 NIRS-ICG measurements. Receiver operating curves for cerebral blood flow (CBF), cerebral blood volume (CBV) 
and mean transit time of indocyanine green (mttICG) obtained by the NeMo® Probe. Data pairs of true positive and false positive rates corresponding to each 
possible diagnostic threshold were plotted. Arrows mark the chosen cutoff value. Dashed lines indicate the line where the area under the curve equals 0.5. 
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Table 1: Mean values, standard deviation and coefficient of variation from 59-pairs of repeated 
NIRS-ICG measurements.  
 
 CBF  
(ml/100g/min)  
CBV  
(ml/100g)  
Mean 
(n=118) 30.1  3.2  
SD  
(n=118) 12.9  1.0  
CV 
(n=59) 10.9% 11.7% 
 
CBF, cerebral blood flow; CBV, cerebral blood volume; CV, coefficient of variation; mttICG, mean 
transit time of indocyanine green; SD, standard deviation 
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Table 2: Measurement values from 122 NIRS-ICG measurements with and without delayed cerebral 
ischemia. Values are expressed as mean ± standard deviation. 
 
 CBF  
(ml/100g/min)  
CBV  
(ml/100g)  
Values without DCI  
(n=70) 36.8 ± 13.8 3.6 ± 1.3 
Values with  DCI  
(n=52) 21.6 ± 6.9 2.8 ± 0.9 
p-value  <0.0001 <0.0001 
 
CBF, cerebral blood flow; CBV, cerebral blood volume; DCI, delayed cerebral ischemia; mttICG, 
mean transit time of indocyanine green 
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Table 3: Correlation between delayed cerebral ischemia and cut-off values from 128 NIRS-ICG 
measurements.  
 
 
 
Cutoff Value Area under the curve 
95%              
confidence interval Sensitivity Specificity 
Po
 
CBF 
 
0.853 
 
0.782 – 0.925 
  
< 20.0 ml/100g/min 
< 25.0 ml/100g/min 
  63% 
85% 
90% 
83% 
     
CBV 0.729 0.638 – 0.821   
< 3.0 ml/100g   73% 69% 
     
mttICG  0.800 0.723 – 0.876   
> 6,5 sec   77% 63% 
 
CBF, cerebral blood flow; CBV, cerebral blood volume; mttICG, mean transit time of indocyanine 
green 
 
 
 
 
 
 
 
 
